Protara Therapeutics, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount
Protara Therapeutics, Inc. (TARA) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount of $325.00 thousand for the 12-month period ending 2018-12-31, per its 10-K filed 2020-03-20.
Discontinued › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2020-03-20
- Protara Therapeutics, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2018 was $325.00K, a 52.83% decline from fiscal 2017.
- Protara Therapeutics, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2017 was $689.00K.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount 12 month |
|---|---|
| 2018-12-31 | $325.00K 10-K · filed 2020-03-20 |
| 2017-12-31 | $689.00K 10-K · filed 2019-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |